Researchers assess the psychosocial impact of allogeneic hematopoietic stem cell transplantation, particularly how preparing patients can assist in guiding health care providers in offering better care.
In managing allogeneic hematopoietic stem cell transplantation (allo-HSCT), clinical outcomes, as well as psychosocial aspects can prove beneficial in improving care delivery. Researchers of a study published in European Journal of Cancer Care sought to better determine the psychosocial impact of the procedure.
Reviewing qualitative studies addressing this impact, researchers have identified a wide range of stressors and various coping mechanisms associated with allo-HSCT that they say shed a light on the social meaning of stressors following the procedure and coping strategies used to re-adjust.
The data from 20 interviews with allo-HSCT survivors revealed 72 stressors across 7 categories:
In addition to a broad array of stressors the interviews also revealed coping mechanisms used by patients included direct efforts to manage problems, such as using a wig or hat for hair loss and avoiding unsafe situations; adaptive attitudes, such as accepting the state of side effects; and seeking and relying on social support.
“The findings of this study have clinical implications for the design and implementation of effective interventions for all-HSCT survivors,” conclude researchers. “Which can improve the quality of care delivered to this group and enhance post-treatment quality of life and adjustment.”
Reference
Kusaka K, Unoguchi H, Nakahara R, et al. Stress and coping strategies among allogeneic haematopoietic stem cell transplantation survivors: a qualitative study. Eur J Cancer Care. Published online September 5, 2020. doi:10.1111/ecc.13307
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More